Derek Archila

Stock Analyst at Wells Fargo

(3.95)
# 619
Out of 5,024 analysts
187
Total ratings
52.46%
Success rate
10.13%
Average return

Stocks Rated by Derek Archila

Apellis Pharmaceuticals
Oct 15, 2025
Upgrades: Overweight
Price Target: $29$32
Current: $25.40
Upside: +25.98%
Kyverna Therapeutics
Oct 8, 2025
Maintains: Overweight
Price Target: $24$27
Current: $7.05
Upside: +282.98%
C4 Therapeutics
Sep 23, 2025
Maintains: Overweight
Price Target: $5$10
Current: $2.65
Upside: +277.36%
aTyr Pharma
Sep 16, 2025
Downgrades: Equal-Weight
Price Target: $25$1
Current: $1.06
Upside: -5.21%
Celldex Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $44$38
Current: $27.00
Upside: +40.74%
Soleno Therapeutics
Aug 20, 2025
Initiates: Overweight
Price Target: $123
Current: $67.19
Upside: +83.06%
Sutro Biopharma
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $4$3
Current: $0.81
Upside: +271.56%
Cabaletta Bio
Aug 8, 2025
Maintains: Equal-Weight
Price Target: $3$2
Current: $2.92
Upside: -31.51%
Ascendis Pharma
Aug 8, 2025
Maintains: Overweight
Price Target: $289$295
Current: $209.89
Upside: +40.55%
Zentalis Pharmaceuticals
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $6$5
Current: $1.63
Upside: +206.75%
Maintains: Equal-Weight
Price Target: $27$26
Current: $22.23
Upside: +16.96%
Maintains: Overweight
Price Target: $19$16
Current: $9.78
Upside: +63.60%
Upgrades: Overweight
Price Target: $67$89
Current: $90.93
Upside: -2.12%
Maintains: Overweight
Price Target: $741$756
Current: $825.02
Upside: -8.37%
Initiates: Overweight
Price Target: $17
Current: $4.72
Upside: +260.17%
Maintains: Overweight
Price Target: $91$129
Current: $111.84
Upside: +15.34%
Maintains: Overweight
Price Target: $57$53
Current: $62.82
Upside: -15.63%
Maintains: Equal-Weight
Price Target: $11$18
Current: $23.33
Upside: -22.83%
Maintains: Overweight
Price Target: $32$25
Current: $10.69
Upside: +133.86%
Maintains: Equal-Weight
Price Target: $11$10
Current: $10.80
Upside: -7.41%
Maintains: Equal-Weight
Price Target: $16$15
Current: $3.55
Upside: +322.54%
Downgrades: Equal-Weight
Price Target: $36
Current: $39.38
Upside: -8.58%
Maintains: Overweight
Price Target: $40$51
Current: $34.22
Upside: +49.04%
Maintains: Equal-Weight
Price Target: $12$14
Current: $19.00
Upside: -26.32%
Maintains: Equal-Weight
Price Target: $11$9
Current: $4.20
Upside: +114.29%
Maintains: Overweight
Price Target: $47$45
Current: $17.81
Upside: +152.67%
Maintains: Overweight
Price Target: $16$11
Current: $3.88
Upside: +183.87%
Maintains: Overweight
Price Target: $12$10
Current: $3.15
Upside: +217.97%
Downgrades: Hold
Price Target: $37$20
Current: $2.56
Upside: +682.78%
Initiates: Buy
Price Target: $18
Current: $5.19
Upside: +246.82%
Upgrades: Buy
Price Target: n/a
Current: $4.23
Upside: -
Downgrades: Hold
Price Target: $298$193
Current: $34.96
Upside: +452.06%
Reiterates: Buy
Price Target: $61$41
Current: $68.19
Upside: -39.87%
Maintains: Hold
Price Target: $480$160
Current: $20.07
Upside: +697.41%
Downgrades: Hold
Price Target: $180$60
Current: $17.38
Upside: +245.22%
Downgrades: Perform
Price Target: $29
Current: $5.38
Upside: +439.03%
Maintains: Outperform
Price Target: $34$50
Current: $1.34
Upside: +3,645.32%
Maintains: Outperform
Price Target: $32$51
Current: $17.41
Upside: +192.94%
Initiates: Outperform
Price Target: $88
Current: $21.32
Upside: +312.76%
Initiates: Market Perform
Price Target: n/a
Current: $23.09
Upside: -
Downgrades: Perform
Price Target: n/a
Current: $19.87
Upside: -